Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Non-Metastatic Nasopharyngeal Cancer: A Single-Center Experience

Introduction

Methods

Patients aged between 18 and 80 years with a Karnofsky Performance Status (KPS) score ?60 and without distant metastasis were included in the study. Pre-existing cases with NPC with RT, multiple cancer diagnosis, and infection at the beginning of treatment were excluded from the study.

Diagnosis and staging of all patients were completed before treatment. NPC was diagnosed by biopsy in endoscopy guide. All patients underwent head and neck magnetic resonance imaging and/or computed tomography, fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET CT) imaging and, if necessary, magnetic resonance imaging of the brain. Staging was based on the Union for International Cancer Control/American Joint Committee on Cancer (7th Edition) TNM staging system.

Treatment Characteristics
Ten early-stage cases (T1-T2N0) received RT alone. Two advanced stage cases received RT alone due to age and/ or comorbidities. Fifty cases with local advanced disease received both RT and concomitant CT. In consideration of the patient's age, KPS, and comorbid diseases, 43 patients were treated with cisplatin 80-100 mg/m² every three weeks, and seven patients were treated with weekly 40 mg/m2 cisplatin CT regimen. Patients were seen at the clinic at least twice a week. Weekly full blood and blood biochemical controls were performed, and side effects were recorded in our patient tracking system. Forty (64.5%) patients were treated with amifostine. The oral intake and weight of the patient were monitored weekly, and oral nutrition solution or intravenous nutritional support was given according to the needs of the patients. Patients were divided into two groups according to their RT modalities as non-intensity-modulated radiotherapy (IMRT) and IMRT groups. Non-IMRT techniques were applied between 2006 and 2013, and IMRT technique was applied to all patients from 2014 to 2017.

Statistical Analysis
Data were analyzed using SPSS 22.0 (released 2013, IBM SPSS Statistics for Windows, version 22.0; IBM Corp., Armonk, NY, USA). Data are expressed as mean±standard error and number and percentage. Shapiro?Wilk test was used to evaluate the normality of the distribution. Variance analysis (ANOVA) was used to determine the differences between group averages, and Tukey's test was used for post hoc tests to determine the differences. Chi-square test was used in the analysis of the generated cross tables. Kaplan? Meier test was used to compare the mean life span, and the log-rank test was used to identify different groups. Significant variables in the univariate analyses were included in a multivariate Cox regression model to identify the most important prognostic factors. A p value <0.05 was considered statistically significant.

Patient Monitoring
Patients were called for control the first month after treatment, every 3 months for the first 2 years, every 6 months until 5 years, and then annually. Detailed head and neck examination and endoscopic evaluation were performed at each control visit. Response evaluation was performed with BT/MR at 1 month after RT and FDG-PET CT at 3 months after RT. If there was a history of cigarette use and clinical indications, thorax CT was required. When local/locoregional relapse or metastasis was detected, treatment decisions were made in multidisciplinary oncology councils.

Results

According to the T stage, 6 (9.7%) were T1, 37 (59.7%) were T2, 11 (17.7%) were T3, and 8 (12.9%) were T4. Thirteen (21.0%) cases were N0, 11 (17.7%) cases were N1, 27 (43.5%) cases were N2, and 11 (17.7%) cases were N3. According to the TNM stage, 4 (6.5%) patients had stage I, 10 (16.1%) had stage II, 29 (46.8%) had stage III, 8 (12.9%) had stage IVa, and 11 (17.7%) had stage IVb. Patient characteristics are summarized in Table 1.

Table 1: Patient characteristics

The median duration of RT was 52 (42?69) days, and the median time interval between RT was 3 (0? 15) days. Adjuvant CT was administered to 49 (79%) cases. Treatment characteristics are summarized in Table 2.

Table 2: Treatment characteristics

Median overall survival (OS) was 55 (10?134) months, whereas median disease-free survival was 44 (6?129) months. The median duration of local control was 48 (6-129) months. Eleven (17.7%) patients developed distant metastases. Distant metastases were detected in 6 (9.7%) patients who had local control. The median weight loss on follow-up during RT was 3 (0? 27) kg. During the follow-up period, 9 (14.2%) cases were diagnosed with hypothyroidism, and 14 (22.5%) cases died due to disease.

OS was 93±8 months for male patients and 126±5 months for female patients (univariate analysis p=0.042 and multivariate analysis p=0.018) (Fig. 1).

Fig 1: OS, female versus male patients.

OS was 62±9 months in patients with a KPS ≤70 and 119±6 months in patients with a KPS >70 (univariate analysis p=0.002 and multivariate analysis p=0.067) (Fig. 2).

Fig 2: OS, KPS>70 versus KPS≤70.

A significant correlation was found between OS and NLR. In our study, a cut-off value of 3 for NLR was accepted because the mean was 3.3±0.3 and the median was 2.5.

Mean OS was 124±5 months in an NLR <3 cases and 69±9 months in an NLR ?3 cases (univariate analysis p=0.008 and multivariate analysis p=0.002) (Fig. 3). The mean OS was 101±9 months in cases with an initial hemoglobin level of ?13 g/dl and 107±8 months in patients with a hemoglobin level >13 g/dl (univariate analysis p=0.498 and multivariate analysis p=0.234).

Fig 3: OS, NLR<3 versus NLR ≥3.

The mean OS was 108±7 months in patients with a baseline platelet value ?250,000/mm3 and 99±10 months with a platelet count >250,000/mm3 (univariate analysis p=0.562 and multivariate analysis p=0.206).

Table 3 summarizes the relationship between hematological blood values and OS.

Table 3: The relationship between hematological blood values and overall survival

Weight loss in the 14 patients who died due to cancer progression was 6.0±8.5, whereas it was 3.9±4.0 in the living cases (univariate analysis p=0.025 and multivariate analysis p=0.006). The mean lactate dehydrogenase (LDH) value was found to be 420.2±131.2 in 14 cases who died due to cancer progression, whereas it was 318.7±117.4 in living cases (univariate analysis p=0.011 and multivariate analysis p=0.063).

The results of the univariate and multivariate analyses of OS are summarized in Table 4.

Table 4: Cox regression analysis: overall survival

Patients without distant metastasis were found to have statistically significantly longer survivals, as expected. The mean OS was 42±6 months in patients with distant metastases and 121±5 months in patients without distant metastases (p<0.001).

When the relationship between distant metastases and NLR was examined, of the 11 metastatic patients, 7 (63.6%) were in the NLR ?3 group, and 4 (36.4%) were in the NLR <3 group (p=0.082).

The six cases with distant metastasis while locoregional control was present were also distributed evenly between the NLR groups (three cases in the NLR ?3 groups and three cases in the NLR <3 group, p=0.661).

NLR status according to some clinical characteristics is shown in Table 5. Mean NLR values according to the TNM stage are shown in Table 6.

Table 5: NLR status according to some clinical characteristics.

Table 6: NLR values according to the TNM stage

Distant metastases were found to be significantly higher in male cases, and all 11 metastatic cases were male patients (Fisher's exact test p=0.012).

At diagnosis, distant metastases were more frequent in the KPS ≤70 group (Fisher's exact test p=0.026). Additional chronic diseases in patients decrease the KPS values of patients. Patients cannot receive synchronous/ adjuvant CT because of comorbidities and secondary low KPS values. It is thought that the increase in the frequency of distant metastases in low KPS patients is due to the lack of CT in their treatment.

The initial hemoglobin level was statistically higher in male patients than in female patients (Fisher's exact test p=0.007); 65% of the female patients had a hemoglobin level ≤13, whereas only 28.6% of male patients were below this level.

Discussion

Inflammation is considered to play an important role in the development of cancer, and inflammation may be a negative factor affecting OS of patients with cancer.[] A statistically significant correlation was found between NLR and OS in the present study. In our study, survival rates were found to be lower in patients with an NLR ?3.

Different cut-off values are available from different studies. Using an NLR limit of 2.7, Sun et al. found that higher NLR values are associated with shorter progression- free survival.[] In another study of NPC, an NLR value of ≥3.6 was associated with shorter progression- free survival, disease-specific survival, and OS. Compared with early-stage disease, the statistical relationship between high NLR and poor prognosis was found to be stronger in advanced stage disease. [] In another study of 229 patients with NPC, the NLR threshold value was accepted as 3.6, and the median survival in the high NLR group was 15.3 months, whereas it was 23.5 months in the low NLR group (p<0.001).[] In the study conducted by Chen et al. of 211 patients with metastatic NPC, OS was lower in the NLR 5 group (univariate analysis p=0.025 and multivariate analysis p=0.019).[] In a study of 140 patients with non-metastatic NPC, the NLR threshold was accepted as 2.28, with a lower progression-free survival and OS rates in the high NLR group (p<0.05).[] In a study of 98 patients with non-metastatic NPC, the NLR limit value was 2.995, and the treatment failure and recurrence rates were higher in patients in the high NLR group (p=0.001).[] A summary of the literature is shown in Table 7. Similarly, NLR is associated with poor prognosis when we examine the literature examples.

Table 7: Literature summary

Neutrophils, an inflammatory cell type, are thought to be involved in different stages of tumor development through the production of various cytokines, such as oncostatin M, hepatocyte growth factor, and transforming growth factor-beta.[] In addition, neutrophils support tumor angiogenesis and also support the release of angiogenic factors, such as vascular endothelial growth factor, angiopoietin-1, and fibroblast growth factor-2.[,] On the other hand, lymphocytes are also responsible for removing tumor cells. [] NPC is usually infiltrated by lymphocytes, such as T helper 17 (Th17) cells. Th17 cells are partially regulated by macrophage migration inhibitory factor, produce high levels of cytokines, including tumor necrosis factor and interferon-γ, and mediate the antitumor effects.[]

For this reason, NLR can affect the survival of patients with NPC by affecting the tumor microenvironment and the immune system. Almost all NLR-related studies in cancer have shown a worsening of the prognosis with higher NLR.[,-] Given the results of various investigations, neutrophil and lymphocyte values appear to provide a balance between inflammation and angiogenesis (neutrophils) and protective immunity (lymphocytes). Disruption of this balance in favor of neutrophils can lead to tumor progression by stimulating angiogenesis.

In the present study, deaths due to disease progression were found to be higher in patients with higher weight loss and those with high pretreatment serum LDH. Weight loss is common in the treatment of NPC. In a study evaluating 2399 patients with NPC, ?4.6% weight loss was evaluated as critical weight loss. Compared with patients without critical weight loss, patients with critical weight loss had significantly lower 5-year OS (72.4% vs. 79.3%, p<0.001), failure-free survival (71.1% vs. 78.4%, p<0.001), and locoregional failure-free survival (78.1% vs. 84.8%, p<0.001), respectively. In the present study, critical weight loss was accepted as a prognostic factor.[] There are many studies investigating pretreatment serum LDH levels in NPC. Turen et al. reported the relationship between LDH and OS in 61 patients with stage III-IV NPCs. Serum LDH level was found to be higher (>460 IU/l) in 24.6% of the patients. LDH level was found to correlate with poor 4-year OS (28.5% vs. 68.7%, p=0.01).[]

Limitations of the Study
Our study has limitations. The limitations of the present study include its retrospective and single-centered design and having a small number of patients.

Conclusion

Peer-review: Externally peer-reviewed.
Conflict of Interest: No conflict of interest was declared by the authors.
Ethics Committee Approval: This study was conducted in accordance with local ethical rules.
Financial Support: No support.
Authorship contributions: Concept - M.A., D.E., A.Ö., S.Ş.; Design - M.A., D.E.; Supervision - M.A., D.E.; Materials - M.A., D.E., A.Ö., S.Ş.; Data collection &/or processing - M.A., D.E., A.Ö., S.Ş.; Analysis and/or interpretation - M.A., D.E., A.Ö., S.Ş.; Literature search - M.A., D.E., S.Ş.; Writing - M.A., D.E., A.Ö., S.Ş.; Critical review - M.A., D.E., A.Ö., S.Ş.

References